Drug Patents owned by Celgene Corp
1. Drug name - IDHIFA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9512107 | CELGENE CORP | Therapeutically active compositions and their methods of use |
Jan, 2033
(10 years from now) | |
| US9738625 | CELGENE CORP | Therapeutically active compounds and their methods of use |
Aug, 2034
(11 years from now) | |
| US10093654 | CELGENE CORP | Therapeutically active compounds and their methods of use |
Aug, 2034
(11 years from now) | |
| US9732062 | CELGENE CORP | Therapeutically active compounds and their methods of use |
Sep, 2034
(11 years from now) | |
| CN105916507A | CELGENE CORP | Therapy Active Compound And Using Method Thereof |
Jan, 2020
(2 years ago) | |
| CN107417667B | CELGENE CORP | Therapeutically Active Compounds And Methods Of Use Thereof |
Jan, 2033
(10 years from now) | |
| CN108912066A | CELGENE CORP | A Therapeutically Active Compound And Using Method Thereof |
Jan, 2033
(10 years from now) | |
| CN107417667A | CELGENE CORP | Therapy Active Compound And Using Method Thereof |
Jan, 2033
(10 years from now) | |
| CN104114543B | CELGENE CORP | Therapeutically Active Compound And Its Using Method |
Jan, 2033
(10 years from now) | |
| CN108912066B | CELGENE CORP | Treating Active Compound And Using Method Thereof |
Jan, 2033
(10 years from now) | |
| CN104114543A | CELGENE CORP | Therapy Active Compound And Using Method Thereof |
Jan, 2033
(10 years from now) | |
| EP3406608A1 | CELGENE CORP | Therapeutically Active Compounds And Their Methods Of Use |
Jan, 2033
(10 years from now) | |
| EP2800743B1 | CELGENE CORP | Therapeutically Active Compounds And Their Methods Of Use |
Jan, 2033
(10 years from now) | |
| EP3406608B8 | CELGENE CORP | Therapeutically Active Compounds And Their Methods Of Use |
Jan, 2033
(10 years from now) | |
| EP3406608B1 | CELGENE CORP | Therapeutically Active Compounds And Their Methods Of Use |
Jan, 2033
(10 years from now) | |
| EP2800743A1 | CELGENE CORP | Therapeutically Active Compounds And Their Methods Of Use |
Jan, 2033
(10 years from now) | |
| EP2800743A4 | CELGENE CORP | Therapeutically Active Compounds And Their Methods Of Use |
Jan, 2033
(10 years from now) | |
| EP3566706B1 | CELGENE CORP | Therapeutically Active Compounds And Their Methods Of Use |
Aug, 2034
(11 years from now) | |
| EP3566706A1 | CELGENE CORP | Therapeutically Active Compounds And Their Methods Of Use |
Aug, 2034
(11 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10610125 | CELGENE CORP | Methods and compositions for cell-proliferation-related disorders |
Jun, 2030
(7 years from now) | |
| US10294215 | CELGENE CORP | Therapeutically active compounds and their methods of use |
Jan, 2033
(10 years from now) | |
Drugs and Companies using ENASIDENIB MESYLATE ingredient
Treatment: Treatment of relapsed or refractory acute myeloid leukemia (aml) with an isocitrate dehydrogenase-2 (idh2) mutation
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| EQ 50MG BASE | TABLET;ORAL | Prescription |
| EQ 100MG BASE | TABLET;ORAL | Prescription |
2. Drug name - ONUREG
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8846628 | CELGENE CORP | Oral formulations of cytidine analogs and methods of use thereof |
Jun, 2030
(7 years from now) | |
Drugs and Companies using AZACITIDINE ingredient
Treatment: Continued treatment of adults with acute myeloid leukemia who achieved first complete remission (cr) or cr with incomplete blood count recovery following intensive induction chemotherapy and are not able to complete intensive curative therapy
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 200MG | TABLET;ORAL | Prescription |
| 300MG | TABLET;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.